Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yago Nieto

Showing results (11-20 of 250) with videos related to

Pageof 25
Sort By:
Journal of the National Comprehensive Cancer Network : JNCCN|December 16, 2014
Progressive multifocal leukoencephalopathy after allogeneic bone marrow transplantation for acute myeloid leukemiaHans C Lee, Victor Mulanovich, Yago Nieto
Springer Seminars in Immunopathology|September 16, 2004
Stem-cell transplantation for the treatment of advanced solid tumorsYago Nieto, Roy B Jones, Elizabeth J Shpall
Current Opinion in Oncology|April 13, 2004
High-dose chemotherapy for breast cancer: is another look warranted?Yago Nieto, Roy B Jones, Elizabeth J Shpall
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 13, 2014
The emerging role of gemcitabine in conditioning regimens for hematopoietic stem cell transplantationEmily Wang, Alison Gulbis, James W Hart, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 9, 2016
Impact of Polymorphic Variations of Gemcitabine Metabolism, DNA Damage Repair, and Drug-Resistance Genes on the Effect of High-Dose Chemotherapy for Relapsed or Refractory Lymphoid MalignanciesKeiji Shinozuka, Hongwei Tang, Roy B Jones, et al.
American Journal of Clinical Oncology|June 1, 2005
Evaluation of the effect of age on treatment-related mortality and relapse in patients with high-risk primary breast cancer receiving high-dose chemotherapyYago Nieto, Elizabeth J Shpall, Scott I Bearman, et al.
Oncotarget|October 16, 2022
HDAC inhibitors suppress protein poly(ADP-ribosyl)ation and DNA repair protein levels and phosphorylation status in hematologic cancer cells: implications for their use in combination with PARP inhibitors and chemotherapeutic drugsBenigno C Valdez, Yago Nieto, Bin Yuan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 2, 2007
Prognostic significance of overexpression and phosphorylation of epidermal growth factor receptor (EGFR) and the presence of truncated EGFRvIII in locoregionally advanced breast cancerYago Nieto, Fatima Nawaz, Roy B Jones, et al.
Oncotarget|February 14, 2022
ABT199/venetoclax potentiates the cytotoxicity of alkylating agents and fludarabine in acute myeloid leukemia cellsBenigno C Valdez, David Murray, Bin Yuan, et al.
Leukemia & Lymphoma|February 21, 2022
Enhanced cytotoxicity of bisantrene when combined with venetoclax, panobinostat, decitabine and olaparib in acute myeloid leukemia cellsBenigno C Valdez, Bin Yuan, David Murray, et al.
Pageof 25

Showing results (11-20 of 250) with videos related to

Sort By:
Pageof 25
Journal of the National Comprehensive Cancer Network : JNCCN|December 16, 2014
Progressive multifocal leukoencephalopathy after allogeneic bone marrow transplantation for acute myeloid leukemiaHans C Lee, Victor Mulanovich, Yago Nieto
Springer Seminars in Immunopathology|September 16, 2004
Stem-cell transplantation for the treatment of advanced solid tumorsYago Nieto, Roy B Jones, Elizabeth J Shpall
Current Opinion in Oncology|April 13, 2004
High-dose chemotherapy for breast cancer: is another look warranted?Yago Nieto, Roy B Jones, Elizabeth J Shpall
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 13, 2014
The emerging role of gemcitabine in conditioning regimens for hematopoietic stem cell transplantationEmily Wang, Alison Gulbis, James W Hart, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 9, 2016
Impact of Polymorphic Variations of Gemcitabine Metabolism, DNA Damage Repair, and Drug-Resistance Genes on the Effect of High-Dose Chemotherapy for Relapsed or Refractory Lymphoid MalignanciesKeiji Shinozuka, Hongwei Tang, Roy B Jones, et al.
American Journal of Clinical Oncology|June 1, 2005
Evaluation of the effect of age on treatment-related mortality and relapse in patients with high-risk primary breast cancer receiving high-dose chemotherapyYago Nieto, Elizabeth J Shpall, Scott I Bearman, et al.
Oncotarget|October 16, 2022
HDAC inhibitors suppress protein poly(ADP-ribosyl)ation and DNA repair protein levels and phosphorylation status in hematologic cancer cells: implications for their use in combination with PARP inhibitors and chemotherapeutic drugsBenigno C Valdez, Yago Nieto, Bin Yuan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 2, 2007
Prognostic significance of overexpression and phosphorylation of epidermal growth factor receptor (EGFR) and the presence of truncated EGFRvIII in locoregionally advanced breast cancerYago Nieto, Fatima Nawaz, Roy B Jones, et al.
Oncotarget|February 14, 2022
ABT199/venetoclax potentiates the cytotoxicity of alkylating agents and fludarabine in acute myeloid leukemia cellsBenigno C Valdez, David Murray, Bin Yuan, et al.
Leukemia & Lymphoma|February 21, 2022
Enhanced cytotoxicity of bisantrene when combined with venetoclax, panobinostat, decitabine and olaparib in acute myeloid leukemia cellsBenigno C Valdez, Bin Yuan, David Murray, et al.
Pageof 25